The stock's fall snapped a four-day winning streak.

Fintel reports that on October 8, 2024, Oppenheimer initiated coverage of Abbott Laboratories (NYSE:ABT) with a Outperform ...

Abbott Laboratories (ABT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

MedTech portfolio is growing at a CAGR (compounded annual growing rate) of 11%-13%. The company’s non-MedTech operations are ...

In a federal tax court petition, Abbott rejects numerous "arbitrary, capricious and unreasonable" determinations the IRS made ...

Abbott Laboratories (ABT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

On Friday, Abbott Laboratories (ABT) stock saw a decline, ending the day at $112.43 which represents a decrease of $-0.30 or -0.27% from the prior close of $112.73. The stock opened at $112.93 and ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Abbott Laboratories reported it achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in electrophysiology: early completion of enrollment in ...

Abbott Laboratories closed $8.30 below its 52-week high ($121.64), which the company achieved on March 8th.